Full-Time

Associate Director

Vaxcyte

Vaxcyte

501-1,000 employees

Develops broad-spectrum vaccines for bacterial infections

Compensation Overview

$190k - $220k/yr

+ Equity component

San Carlos, CA, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Inventory Management
GMP
Data Analysis

Get referred to Vaxcyte

See people who can refer or advise you

Requirements
  • A PhD in Biochemistry, Immunology, Analytical Chemistry, Biological Sciences, or a related discipline with at least 7 years of relevant biopharmaceutical industry experience, or an M.S. in a related discipline with at least 10 years of relevant biopharmaceutical industry experience.
  • Significant hands-on experience with antibody reagent generation, screening, characterization, qualification, conjugation, labeling, lot bridging, stability assessment, and lifecycle management.
  • Experience managing immunoassay critical reagents, reference standards, assay controls, calibrators, and customized assay materials used in ligand-binding assays or vaccine analytical methods.
  • Experience planning, executing, and interpreting critical reagent and reference material stability studies, including protocol design, storage condition selection, timepoint testing, acceptance criteria, trend analysis, expiry or retest dating recommendations, and stability reporting.
  • Strong understanding of antibody-antigen interactions, assay reagent quality attributes, specificity, affinity, cross-reactivity, epitope behavior, matrix effects, reagent stability, and lot-to-lot comparability.
  • Experience developing and executing qualification strategies for critical reagents and reference materials, including acceptance criteria, bridging approaches, stability monitoring, lifecycle planning, and replenishment planning.
  • Hands-on experience with immunoassay platforms such as MSD, ELISA, electrochemiluminescence-based assays, multiplex assays, or other ligand-binding assay technologies.
  • Experience with customized immunoassay materials such as MSD plates, coated plates, labeled detection reagents, multiplex panels, assay kits, buffers, and other platform-specific critical components.
  • Experience supporting immunoassay method development, troubleshooting, optimization, method transfer, validation readiness, platform evaluation, or routine analytical testing.
  • Proven ability to troubleshoot reagent- or reference-material-related performance trends using structured, data-driven root-cause analysis approaches.
  • Demonstrated ability to oversee outsourced reagent generation, characterization, qualification, stability, custom assay material production, or testing activities.
  • Demonstrated ability to support daily laboratory operations, including reagent and reference material planning, study scheduling, inventory management, data review, documentation, and technical support.
  • Solid understanding of protein chemistry, polysaccharide chemistry, conjugation chemistry, antibody engineering or production, reagent conjugation, and biological sample matrix effects as applied to vaccine analytical development.
  • Strong organizational skills demonstrated through management of reagent inventories, reference material inventories, documentation systems, stability schedules, external deliverables, timelines, and cross-functional priorities.
  • Strong scientific judgment and the ability to make sound technical recommendations when working with incomplete, complex, or conflicting data.
  • Strong written and verbal communication skills for clearly communicating technical concepts, study results, risks, and recommendations to cross-functional stakeholders, external partners, and regulatory audiences.
  • Commitment to data integrity, documentation quality, scientific excellence, accountability, supply continuity, and continuous improvement.
Responsibilities
  • Contribute to establishing and growing the Immunoassay Development Capability within Global Analytical Development, with primary responsibility for immunoassay critical reagents, reference materials, customized assay materials, stability programs, and associated lifecycle management systems.
  • Engage daily in laboratory operations, including reagent planning, reference material planning, sample and material readiness, laboratory study coordination, inventory review, data review, documentation, and hands-on technical support.
  • Lead the generation, characterization, qualification, stability planning, lifecycle management, and inventory control of antibody reagents used in immunoassays.
  • Support antibody reagent generation strategies, including antigen design, immunization strategy, hybridoma or recombinant antibody generation, screening, clone selection, purification, conjugation, labeling, characterization, and long-term supply planning.
  • Develop and execute antibody characterization plans covering specificity, affinity, cross-reactivity, epitope behavior, lot-to-lot comparability, assay performance attributes, stability, and suitability for intended immunoassay use.
  • Lead the generation, characterization, qualification, bridging, stability planning, lifecycle management, and inventory control of reference materials, including reference standards, assay controls, calibrators, system suitability controls, bridging controls, and other assay performance control materials.
  • Design and execute critical reagent and reference material stability studies, including protocol development, storage condition assessment, timepoint planning, testing strategy, acceptance criteria, data interpretation, trend evaluation, expiry or retest dating recommendations, and stability report generation.
  • Lead the generation, characterization, qualification, and lifecycle management of customized immunoassay critical materials, including MSD plates, coated plates, Sulfo-TAG or other labeled detection reagents, bead-conjugated reagents, multiplex assay components, customized assay kits, buffers, blocking reagents, and other platform-specific critical materials.
  • Develop qualification and bridging strategies for new critical reagent lots, reference material lots, and customized assay material lots to support continuity of assay performance and data comparability.
  • Establish and maintain critical reagent and reference material inventory systems, including stock planning, usage forecasting, storage conditions, chain of custody, expiry or retest dating, reserve strategy, stability monitoring, documentation, and replenishment planning.
  • Partner with immunoassay development scientists to understand method-specific reagent requirements, assay design, critical material attributes, platform considerations, assay controls, and long-term control strategy needs.
  • Support immunoassay method development, optimization, troubleshooting, transfer, validation readiness, and routine analytical testing as needed.
  • Provide hands-on laboratory support for reagent characterization, reference material characterization, stability studies, assay qualification studies, bridging studies, comparability assessments, platform evaluation studies, and routine non-GMP or GMP-supporting analytical testing.
  • Lead or support investigations of reagent or reference material performance trends using structured, data-driven root-cause analysis approaches and clear experimental plans.
  • Oversee outsourced activities related to antibody generation, reagent manufacturing, reference material preparation, custom MSD plate production, customized kit generation, reagent characterization, stability studies, and critical material qualification.
  • Manage CRO, CDMO, contract testing laboratory, reagent vendor, and technology partner relationships, including technical scope definition, vendor selection support, statement of work input, protocol review, study monitoring, data review, scientific and technical problem-solving, timeline tracking, and deliverable acceptance.
  • Review and approve, as appropriate, external study plans, protocols, batch records, certificates of analysis, characterization reports, qualification reports, stability data, inventory records, and technical summaries related to critical reagents and reference materials.
  • Establish best practices for critical reagent documentation, including reagent history files, qualification packages, characterization reports, stability protocols and reports, inventory records, usage logs, certificates of analysis, lot-release records, bridging reports, and lifecycle management plans.
  • Support ASAT, QC, Quality, Regulatory, and external testing partners in method transfer, validation support, change control, deviation investigation, CAPA, reagent replenishment, reference material replenishment, and long-term assay lifecycle management.
  • Contribute to regulatory submissions, health authority responses, technical reports, method development reports, validation strategies, comparability packages, and BLA-supporting documentation related to critical reagents, reference materials, stability programs, and immunoassay control strategies.
  • Represent the CMC Immunoassay group in cross-functional project teams, technical reviews, vendor meetings, external collaborations, and governance forums as needed.
  • Mentor and provide technical guidance to laboratory scientists on reagent handling, reference material handling, characterization methods, stability study execution, qualification studies, troubleshooting, documentation, and good laboratory practices.
Desired Qualifications
  • Experience working with CROs, CDMOs, contract testing laboratories, reagent vendors, or external technology partners.
  • Experience working in or supporting GMP-regulated analytical environments, including familiarity with method qualification, validation, transfer, change control, deviations, investigations, CAPA, data integrity, critical reagent control, and lifecycle management.
  • Direct experience with conjugated vaccines, polysaccharide-protein conjugates, multivalent vaccines, or other complex biologics.
  • Experience supporting late-stage development, PPQ readiness, BLA preparation, commercial launch, or lifecycle management of vaccine or biologics programs.
  • Direct experience supporting critical reagents or reference materials used for GMP release and stability testing.
  • Experience with antibody discovery, hybridoma generation, recombinant antibody production, antibody purification, antibody conjugation, biotinylation, ruthenium labeling, fluorescent labeling, or bead conjugation.
  • Hands-on experience with MSD platforms, including custom plate coating, labeled detection reagents, and assay reagent qualification.
  • Hands-on experience with Luminex or other multiplex immunoassay platforms, including bead coupling, bead characterization, multiplex panel design, and lot bridging.
  • Experience managing outsourced antibody generation, reagent manufacturing, reference material preparation, customized assay kit production, stability studies, or critical reagent qualification with CROs, CDMOs, or reagent vendors.
  • Experience developing critical reagent control strategies, reagent history files, lifecycle management plans, stability protocols, bridging protocols, inventory control systems, and reagent replenishment strategies.
  • Experience contributing to health authority responses or regulatory submissions on analytical methods, critical reagents, reference standards, stability programs, potency assays, antigenicity assays, or immunoassay control strategies.
  • Experience helping build or scale analytical capabilities, critical reagent programs, or laboratory teams within a growing organization.
  • Experience with multivalent or highly complex vaccine programs.
  • Experience with automation, high-throughput reagent characterization workflows, electronic inventory systems, LIMS, ELN, and digital data analysis tools.

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 enrollment completion removed major execution risk across three Phase 3 trials.
  • VAX-A1 entered first-in-human dosing in June 2026, expanding the pipeline beyond pneumococcus.
  • PCV31 adult data could support a BLA submission and U.S. commercial launch in 2027.

What critics are saying

  • OPUS-1 topline data lands in Q4 2026; any miss crushes VAX-31's valuation.
  • June 30, 2026 cash was $2.51 billion, but operating burn stays punishing.
  • VAX-31 failure leaves Vaxcyte a pre-revenue vaccine company with no approved products.

What makes Vaxcyte unique

  • Vaxcyte's XpressCF platform and 31-valent PCV31 target higher serotype coverage than PCV20.
  • OPUS-1, OPUS-2, and OPUS-3 fully enrolled 6,191 adults by August 2026.
  • Thermo Fisher's up to $1 billion U.S. fill-finish deal secures commercial manufacturing capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

1%
Yahoo Finance
Jun 1st, 2026
Vaxcyte completes VAX-31 Phase 3 trial enrollment, shares rise 8.7%

Vaxcyte shares rose 8.7% after completing enrollment for three Phase 3 adult trials of its VAX-31 pneumococcal vaccine candidate and a Phase 2 infant study. The company also announced plans to begin a Phase 1 adult trial for its VAX-A1 Group A Strep programme. The milestone reduces execution risk whilst advancing Vaxcyte's two-pillar strategy targeting both adult and paediatric pneumococcal markets. The company's narrative projects $224.6 million revenue by 2029, representing an earnings increase of approximately $794.7 million from current levels. Some analysts forecast Vaxcyte reaching $424 million revenue by 2029. Key near-term catalysts include OPUS-1 Phase 3 adult data readout, though higher research and manufacturing spending may pressure the company's cash runway before late-stage outcomes are determined.

GlobeNewswire
Apr 7th, 2026
Vaxcyte to present at the 25th Annual Needham Virtual Healthcare Conference.

Vaxcyte to present at the 25th Annual Needham Virtual Healthcare Conference. April 07, 2026 16:05 ET | Source: Vaxcyte, Inc. SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company's carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company's PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF(R), its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte's pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com. Jeff Macdonald, Executive Director, Investor Relations Vaxcyte, Inc. 917-371-0940 [email protected]

MJH Life Sciences
Mar 28th, 2026
Vaxcyte announces significant development of first-of-its-kind PCV31.

Vaxcyte announces significant development of first-of-its-kind PCV31. With the OPUS-1, 2, and 3 trials underway, Vax-31 has the potential to become the first pneumococcal vaccine of its kind, demonstrating never-before-seen impacts on disease burden. Vaxcyte recently announced significant progress in the clinical development of VAX-31, its 31-valent pneumococcal conjugate vaccine (PCV31) candidate, according to a news release.[1] As the highest-valent PCV currently under development, VAX-31 is being positioned as a potential best-in-class protection against pneumococcal disease for both adults and infants. "The continued advancement of VAX-31 in adults reflects disciplined execution across our phase 3 clinical program, which was finalized in consultation and alignment with the FDA, as we work toward delivering a best-in-class, next-generation PCV with the potential to set a new standard of care for adults and children," Grant Pickering, CEO and co-founder of Vaxcyte, said in the news release. "In adults, evaluating VAX-31 in settings that reflect real-world vaccination practice, including coadministration with a seasonal influenza vaccine and in individuals with prior pneumococcal vaccination, will provide important insights into how VAX-31 is expected to perform across the adult population." Dosing has commenced in the phase 3 OPUS-2 trial, which evaluates the vaccine's performance when administered concomitantly with seasonal influenza vaccines in pneumococcal-naïve adults 50 years and older. Simultaneously, Vaxcyte completed enrollment for a phase 2 infant dose-finding study, marking a critical step toward addressing the leading cause of vaccine-preventable deaths in children under 5 globally.[1] For pharmacists, who serve as the most accessible members of the health care team, these advancements represent a vital expansion of the tools available to combat infectious disease burden, which saw invasive pneumococcal disease (IPD) incidence nearly double between 2012 and 2024.[2,3] The clinical relevance of VAX-31 is underscored by its design to cover approximately 95% of invasive pneumococcal disease (IPD)-causing serotypes circulating in US adults over 50 years.[1] This broad spectrum is necessary because, despite the efficacy of current options like PCV20 and the recently approved PCV21, the phenomenon of serotype replacement continues to push nonvaccine serotypes into prominence.[3] To provide pharmacists and the FDA with real-world data, the OPUS-2 trial utilizes a randomized, double-blind approach to compare concomitant and sequential administration with flu shots, and the upcoming OPUS-3 study will specifically evaluate VAX-31 in adults who have previously received other pneumococcal vaccines, such as the 23-valent pneumococcal polysaccharide vaccine (PPSV23) or PCV20.[1] The push for higher valency, however, brings technical challenges regarding immunogenicity. Research comparing earlier vaccines like PCV7 and PCV13 with newer PCV15 and PCV20 formulations suggested that increasing the number of polysaccharides can sometimes result in lower antibody responses for common serotypes, according to the Canada Communicable Disease Report.[4] To mitigate this, some pipeline candidates - such as Inventprise's PCV25 - are utilizing innovative hydrazide-polyethylene glycol-hydrazide (Hz-PEG-Hz) linker technology to reduce carrier-induced immune interference.[2] Vaxcyte's own platform similarly aims to maintain robust immune responses while expanding coverage, a necessity as the CDC recently lowered the routine vaccination age to 50 years old.[1,5,6] In the pediatric sector, VAX-31 is designed to protect against approximately 92% of IPD serotypes and 96% of acute otitis media cases in children.[1] This is particularly important because PCVs provide nasal immunity by stimulating antibodies in the nasal mucosa, which prevents colonization and is a feature missing from PPSV23.[6] Furthermore, dosing schedules remain a point of clinical discussion, and the World Health Organization supports a 2+1 schedule for healthy children. However, some data indicates that a 3+1 schedule provides superiority.[4] Vaxcyte's ongoing infant study follows the 4-dose series to ensure maximum protection.[1] As the landscape shifts toward sophisticated platforms like Vaxcyte's cell-free protein synthesis system, the goal remains a serotype-independent vaccine - the holy grail of the pneumococcal vaccine industry.[1,7] Pharmacists can bridge current gaps by using the PneumoRecs VaxAdvisor app to navigate complex guidelines and stay updated on Vaxcyte's expanding pipeline, which also includes candidates for Group A Streptococcus and Shigella.[1,2,5] With Vaxcyte committing up to $1 billion toward US manufacturing, the infrastructure is being set to support these next-generation preventions.[1] "We expect to announce topline data from the ongoing OPUS-1 Phase 3 pivotal, noninferiority trial in the fourth quarter of 2026 and results from these additional Phase 3 adult studies in the first half of 2027, keeping us on track toward a planned Biologics License Application submission," concluded Pickering, according to the release. Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for its. References. 1. Vaxcyte advances adult and infant programs for VAX-31, a potential best-in-class, next-generation pneumococcal conjugate vaccine. News release. Vaxcyte, inc. january 22, 2026. Accessed march 18, 2026. https://www.biospace.com/press-releases/vaxcyte-advances-adult-and-infant-programs-for-vax-31-a-potential-best-in-class-next-generation-pneumococcal-conjugate-vaccine. 2. Nowosielski B. New 25-valent pneumococcal vaccine shows promise in global disease coverage. Drug Topics. March 13, 2026. Accessed march 18, 2026. https://www.drugtopics.com/view/new-25-valent-pneumococcal-vaccine-shows-promise-in-global-disease-coverage. 3. Nowosielski B. Rise in IPD calls for development of more pneumococcal vaccines. Drug Topics. November 17, 2025. Accessed march 18, 2026. https://www.drugtopics.com/view/rise-in-ipd-calls-for-development-of-more-pneumococcal-vaccines. 4. De wals P. PCV13, PCV15 or PCV20: which vaccine is best for children in terms of immunogenicity? Can commun dis rep. 2024 jan 1;50(1-2):35-39. doi: 10.14745/ccdr.v50i12a04. 5. Pneumococcal vaccine recommendations. CDC. February 25, 2026. Accessed march 18, 2026. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html. 6. Katella K. Should i get the pneumococcal vaccine? 5 things to know. Yale medicine. December 12, 2024. Accessed march 18, 2026. https://www.yalemedicine.org/news/should-i-get-the-pneumococcal-vaccine-5-things-to-know. 7. Musher DM, anderson R, feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia (nathan). 2022 sep 25;14(1):5. doi: 10.1186/s41479-022-00097-y. Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Simply Wall St
Mar 8th, 2026
Vaxcyte reports $766M loss and raises $408M in follow-on offering amid widening cash burn

Vaxcyte reported a full-year 2025 net loss of $766.63 million and completed a $408.1 million follow-on equity offering in February 2026. The biotech company also filed an additional $500 million at-the-market programme and a $473.86 million shelf registration for employee stock plans. The funding moves underscore Vaxcyte's reliance on equity financing to support its pneumococcal vaccine pipeline, particularly its OPUS Phase 3 programme for VAX-31. Whilst the capital raises improve funding flexibility, they raise concerns about shareholder dilution and mounting cash burn. Simply Wall St community fair value estimates for Vaxcyte range widely from $10.90 to $109 per share. The company's shares may be trading 35% above fair value despite recent declines, according to the analysis.

Vaxcyte
Feb 3rd, 2026
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Vaxcyte, Inc.

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share.